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BACKGROUND: As age increases, prevalence of type 2 diabetes in the U.S. rises
dramatically as the population approaches and enters Medicare eligibility (CDC).
Although ensuring category access, CMS formulary guidelines for Medicare Part D
(MPD) coverage do not take into account the effects of cost-sharing burden on
patient compliance. Literature demonstrates that patient adherence is reduced
with higher copayment costs and consequently, the beneficial clinical impactsmay
likely be unrealized for many patients. OBJECTIVES: To investigate access to dia-
betic medications for MPD patients compared to commercially covered lives. Ex-
ploring copay differentials amongst these populations, insight is gained on how
MPD differs from commercial access to diabetes medications.METHODS: Analysis
of the Walters Kluwer Pharma Solutions Source Longitudinal Patient Database,
sampling of 26.7 million commercial lives and 5 million Medicare Part D lives in
2009. Low Income Subsidy covered lives were excluded. RESULTS: Average drug
copayment for metformin and sulfonylurea for commercial and MPD patients is
$15 and $19 respectively. Average drug copayment for insulin glargine in commer-
cial is $17 and $27 for MPD patients, for branded pioglitazone $31 and $52, and
exenatide $32 and $68. CONCLUSIONS: Copayment differentials across these pop-
ulations are small for generic therapies and grow larger for branded, novel diabetic
agents. This data would suggest a broader, more inclusive review is needed to
assess how the financial burden felt by MPD diabetes patients affects patient com-
pliance and outcomes. Further investigation is needed to study the potential value
that CMS would benefit from re-evaluating the cost sharing burden for this patient
population.
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BIOMARKERS: A CHANGING PARADIGM FOR DEVELOPMENT
Pardini AT, Saraf S, Sparrowhawk K
PriceSpective Ltd., London, UK
The general perception is that pharma companies generally incorporate biomarker
(BM) development into their processes when a drug response is not optimal follow-
ing the results of phase 3 studies. Usually this is when poorer than expected effi-
cacy results are achieved. In this scenario, the BM development enables targeting
of a niche population that is representative of the responders, thus effectively
increasing the efficacy making the product more attractive to payers and health-
care professionals. This late stage approach to BM development also fits with the
commonly held belief that BMs are linked to reduced market access (MA), lower
market shares and decreased product revenues. In such a situation BMs are often
only developed retrospectively to overcome access issues. Our objective is to dem-
onstrate that investment into BMs in the early phase of drug development (DD) is
more commercially attractive. METHODS: Three scenarios of drug development
were defined: 1) the current/traditional model, 2) where biomarker development
is incorporated from phase I of development and 3) where biomarker develop-
ment involves a concurrent Phase III investigation or Phase IV retrospective
analysis. These scenarios were analyzed to determine the relationship between
risk and reward using assumed cash-flow curves and net-present value analysis
based upon those curves. In each case, the implications of integration of BM
development at various stages and how this affects risk-reward were assessed.
RESULTS AND CONCLUSIONS: The scenario analysis demonstrates that by shift-
ing investment to earlier in the DD process, costs associated with investment-
heavy Phase III will be reduced. Early incorporation of BMs into DDwill improve the
commercial and healthcare benefits and the drug will have the potential to benefit
from shortened approval time, early MA and higher price.
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THE CASE OF RARE DISEASE DRUGS BEFORE AND AFTER THE INTRODUCTION
OF PRICING BODIES: LESSONS LEARNED FROM BRAZIL AND CANADA,
IMPLICATIONS FOR THE UNITED STATES
Cost P, Snyder T, Zaidi Q
HERON Evidence Development LLC, Somerville, NJ, USA
OBJECTIVES: This poster examines the pharmaceutical price implication for rare
disease products in two countries which recently developed technology assess-
ment and pricing processes with a look toward the potential implications for the
United States. METHODS: Case studies are built out of examining prices for the
Multiple Sclerosis drugs interferon beta-1a and natalizumab in the context of Bra-
zil, while the Gaucher’s disease products imiglucerase andmiglustat are studied in
Canada. In each case, a brief overview of the health systems is given, with specific
attention to the pricing bodies. The prices for drugs which came to market before
and after the advent of a pricing body are compared relative to each other. These
differences are then compared to the price differential in the US and UK to deter-
mine if the HTA bodywas instrumental in this pricing change. RESULTS: In Canada
miglustat is 17.8% of the cost for imiglucerase while in the US it is 38%, with a
similar trend in the price of MS drugs in Brazil. To some degree, the lower price is
expected as the drug classes are different. However, the disparity between a 17.8%
differential and a 38% differential suggests that the Canadian pricing body is used
to apply downward pressure on the price of rare disease drugs.CONCLUSIONS:The
price differential has distinct implications for the USmarket, in which payers may
look towards developing a technology assessment process using cost effectiveness
research to drive down costs due to the current environment. As one of the most
important markets for pharmaceutical profits, this has considerable ramifications
for industry in terms of income and innovation incentive.
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AN OUTCOMES PROFILE REGISTRY FOR ESTABLISHING A BASELINE MATRIX IN
COMPARATIVE EFFECTIVENESS STUDIES IN PREDICTIVE PHARMACOLOGY
Wheeler C
NTELX, Inc, Vienna, VA, USA
We propose a novel applied decision analytics solution in clinical outcomes anal-
ysis for deriving outcomes to be used as benchmarks in designing appropriate
therapies in personalized medicine and predictive pharmacology. The efficacy of
comparative effectiveness research in clinical medicine and pharmacology is lim-
ited by the lack of a defined solution to derive clinical outcomes across diverse
patient populations and a variety of disparate data sources that collectively define
a clinical profile at particular point in time. An outcome at timeT1 is driven not only
by static factors such as race, ethnicity and occupation, that are generally time-
independent, but also by the condition profile and resultant outcome of the pa-
tient’s condition at T0. Our solution is an ensemble analytical framework that
leverages a temporal rule induction algorithm to create derived outcomes profiles
across the time continuum. It performs analysis on structured and unstructured
data from EMR/EHR, clinical, biological, biomarker, behavioral and demographic
data sources that are integrated into a composite data warehouse via our propriety
semantic resolution and natural language processing algorithms. The outcomes
profiles reflect an index or aggregate score for the amalgamation of all available
data for a particular patient at a particular time. Outcomes profiles from thousands
of samples are catalogued and normalized in a registry and are used to establish a
baselinematrix for application in higher level statistical and predictive analyses for
comparative effectiveness studies in pharmacology. Using this approach, it is pos-
sible to determine based on available data both the appropriate treatment to affect
a desired outcomeand the predicted outcomebased on a given treatment at a given
time.
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BIOSIMILARS LITERATURE REVIEW: THE CURRENT LANDSCAPE AND
IMPLICATIONS OF RECENT HEALTH CARE LEGISLATION FOR THE UNITED
STATES MARKET
Maiese BA, Lee EH, Toscani MT
Jefferson School of Population Health, Philadelphia, PA, USA
Biosimilars represent an emerging area of interest for the pharmaceutical industry.
Biosimilars are essentially ’generic’ versions of ‘branded’ biologics, but are not
considered identical to the innovator biologic. In 2009, half of the top ten selling
drugs were biologics; this proportion is expected to reach 80% by 2015. Biosimilars
are seen as a cost-saving alternative to payers, and as generic drugs take over the
market, manufacturers are depending on biologics to drive growth. However, they
will need to consider the inherent challenges in this market. This literature review
was undertaken to provide a summary of the current state of affairs with biosimi-
lars, including a review of the recent healthcare legislation and policies in coun-
tries that already have formal guidance regarding biosimilars approval. Significant
resources are required to participate in the biosimilars market, including regula-
tory expertise, manufacturing capabilities, and global market reach. One concern
to potential market players is the uncertainty regarding the approval process for
biosimilars in the United States (U.S.). The Patient Protection and Affordable Care
Act (PPACA 2009) authorized the FDA to develop an abbreviated regulatory path-
way for biosimilar approval but guidance has not yet been issued. It is important for
the U.S. to learn from other countries. This review includes a summary of other
countries’ approaches to biosimilars approval. For example, since 2006, the Euro-
pean Medicines Agency has had extensive requirements for pre-clinical and clini-
cal data to demonstrate quality, safety, and efficacy of the product seeking ap-
proval. Questions remain including: How will the competitive landscape look as
biosimilars enter the market? What will be the comfort level with substitutability
of biosimilars?Will there be patent protection for themanufacturing process? And,
what will the FDA require in terms of clinical trials and other supportive data to
recognize biosimilars? The literature review will address these questions and
more.
PHP111
OVER INFLATION OF THE GENETIC CONTRIBUTION TO SCHIZOPHRENIA:
IMPLICATIONS FOR NOVEL THERAPEUTICS
Fleming M, Martin CR
University of the West of Scotland, Ayr, UK
The biologicalmodel of schizophrenia remains the dominantmodel withinmental
health services andhas a powerful and enduring influence on the prevailing format
of mental health care delivery to patients with the diagnosis. There exists almost
universal acceptance of a genetic cause for schizophrenia though in many in-
stances this conflicts both philosophically and clinically with a person-centred
recovery orientated approach. A reviewof the underpinning research that supports
the genetic argument was conducted. Appraisal of family, twin and adoption stud-
ies uncovers serious flaws in the methodologies and statistical analyses used in
studies. These flaws tend to artificially inflate the perceived genetic contribution to
schizophrenia and moreover may also invalidate many of the reported study find-
ings. There exists an absence of a replicable and consistent finding indicating a
clear genetic pathway to schizophrenia. Novel therapeutic approaches aimed at
neurotransmitter receptor site abnormalities should not therefore be discouraged
by any fundamental refocus on gene therapy approaches.
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DEFINITIONAL CRITERIA FOR CHRONIC FATIGUE SYNDROME: A CRITICAL
REVIEW
Christley Y, Duffy T, Martin CR
University of the West of Scotland, Ayr, UK
Chronic Fatigue Syndrome (CFS) is an enigmatic andmisunderstood clinical entity.
A broad range of etiologicalmechanismshave been suggested including endocrine,
immune, infectious, muscular and neurological abnormalities. However, the cause
remains elusive thus impacting on developing models of evidenced based thera-
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peutic intervention and trial monitoring and outcome evaluation. Complicating
this situation is inconsistencies in CFS case definition. The main objective is to
provide a critical review of the similarities and differences between the varying
approaches to CFS case definition. The conflicts and controversies that have
emerged as a result of the differing definitional criterion for CFS are highlighted
and the potential impact on future research is identified. A critical review of the
most frequently used case definitions in CFS was conducted. There are currently
five case definitions of CFS; however, the most prominent is the 1994 Centre for
Disease Control and PreventionCaseDefinitions. However, prima face comparative
advantages of this definition are elusive and indeed, it has been widely criticized
for its lack of specificity. Counterintuitively, there is little compelling evidence to
support the efficacy of any of the case definitions have produced evidence to dem-
onstrate their accuracy or precision at defining cases of CFS. A summary descrip-
tion of the symptom profile for each of the case definitions is provided. The incon-
sistencies that have emerged in CFS research as a consequence of differing
approaches to case definition are contrasted and discussed. Clinical and research
implications are highlighted.
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IQWIG AND HIQA, WHAT ARE THEY GOOD FOR? THE EVOLUTION OF THE HTA
AGENCY: TIME FROM CREATION TO FIRST ASSESSMENT AND IMPACTFUL
APPRAISAL
Green MJ
HERON Evidence Development LLC, Somerville, NJ, USA
OBJECTIVES: To evaluate the time spent from the creation or charter of an HTA
agency to endpoints indicating their effectiveness, such as publication of assess-
ments and evidence of the incorporation of assessment into meaningful appraisal
influencing patient access to health technologies. METHODS: This study looks at
the creation ofHTAagencies (e.g. AHRQ,HIQA, IQWiG, PBAC, CADTHandNICE) and
their evolution in terms of roles in assessment (advisory, coordinating, decision-
making) and the relationship they have with appraisal. RESULTS: It has been dem-
onstrated that the time it takes for an agency to generate assessments impacting
patient access varies widely. For example, in Ireland, HIQA was chartered in May
2007, and entrustedwith performingHTA assessments. In 2008 and 2009, HIQA has
published one health technology assessment per year, both ofwhichwere received
and in turn implemented by the Minister for Health and Children. In comparison,
NICE in the UK was founded in 1999, but its appraisals were not supported by
mandate until 2005. Meanwhile, HTAs driven by DAHTA@DIMDI in Germany are
known to rarely play a role in pricing and reimbursement. CONCLUSIONS: The
evolution of HTA bodies has varied from country to country. However, evolution in
scope and impact may provide useful lessons for countries where HTA is receiving
renewed emphasis or where appraisal is under consideration for implementation,
especially as new agencies are created and existing agencies evolve.
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OPTIMIZING THE ORGANIZATION; MIGRATING HEALTH SERVICES RESEARCH
OPERATIONS INTO THE COLLABORATIVE SCIENCE CENTER OF EXCELLENCE
Benson J, Enterline L
Bristol-Myers Squibb, Plainsboro, NJ, USA
The execution and management of Health Services Research projects can be an
onerous task. Often there is no centralized body of knowledge within an organiza-
tion around process and requirements. This leads to long execution timelines,
difficulties with vendors and ultimately reduced productivity. The Collaborative
Science Center of Excellence (CSCoE) was established in 2008 at Bristol-Myers
Squibb (BMS). This group manages the global operations of a wide variety of pro-
grams, a portion of which includes worldwide investigator sponsored research,
non-clinical research, expanded access, and risk evaluation and mitigation pro-
grams. Beginning June 2009, operational management of the entire US Health Eco-
nomics and Outcomes Research (HEOR) book of work was moved from the OR
Scientists into the CSCoE. This included administration, contract execution, mas-
ter service agreement negotiation, financial management, protocol writing, AMCP
dossier updates, and invoice tracking and payment. Within the first year over 90
projectsweremigrated into the CSCoE. Benefits theHealth Services Research group
realized included: 1. A consolidated 2010 and planned 2011 book of work; 2. A
reportable repository of project information; 3. HEOR protocol and AMCP dossier
improvement through standardization of in-house scientific writing; 4. Expedited
contract execution; 5. Innovative cost-sharing; 6. Tiered and batched review of
contracts reduced corporate legal hours; 7. Rapid response to organizational que-
ries. Centralized process management unlocked latent value by allowing OR Sci-
entists to focus on value-added activities, increased organizational transparency
and agility, and moved operations to a lower cost environment.
POSTER SESSION I:
DISEASE-SPECIFIC STUDIES
Cardiovascular Disorders – Clinical Outcomes Studies
PCV1
DOES ROUTE OF ADMINISTRATION FOR ESTROGEN HORMONE THERAPY
IMPACT RISK OF VENOUS THROMBOEMBOLISM: ESTRADIOL TRANSDERMAL
SYSTEM VERSUS ORAL ESTROGEN-ONLY HORMONE THERAPY
Laliberté F1, Dea K1, Duh MS2, Kahler KH3, Rolli M3, Lefebvre P1
1Groupe d’analyse, Ltée, Montreal, QC, Canada, 2Analysis Group, Inc., Boston, MA, USA,
3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
OBJECTIVES: To evaluate the risk of developing venous thromboembolism (VTE)
events associated with the use of estradiol transdermal system (ETS; Vivelle-Dot®)
relative to oral estrogen-only hormone therapy (HT) agents. METHODS: A health
insurance claims analysis was conducted using the Thomson Reuters MarketScan
database from January 2002 through October 2009. Patients 35 years old newly
initiated on an ETS or oral estrogen-only HT with 2 dispensings were analyzed.
VTE was defined as 1 diagnosis code for deep vein thrombosis or pulmonary
embolism. As a secondary outcome we assessed incident VTE resulting in hospi-
talization. Cohorts of ETS and oral estrogen-only HT were matched 1:1 based on
both exact factor and propensity score matching. Incidence rate ratio (IRR) was
used to compare the rates of VTE between the matched cohorts. Remaining base-
line imbalances from matching were included as covariates in multivariate
adjustments. RESULTS: Among the matched ETS and oral estrogen-only HT users
(27,018 subjects in each group), the mean (SD) ages of the cohorts were 48.9 (7.1)
years; in each cohort 6,044 (22.4%) and 1,788 (6.6%) patients had ahysterectomyand
an oophorectomy at baseline, respectively. The mean (median) drug exposure for
the ETS and oral estrogen-only HT cohorts was 391 (264) and 401 (272) days, respec-
tively. A total of 115 ETS users developed VTE compared to 164 subjects in the
estrogen-only HT cohort (unadjusted IRR: 0.72; 95% CI: 0.57-0.91, P0.006). After
adjustments, ETS remained statistically significantly associated with a lower inci-
dence (33% reduction; P0.0134) of VTE. The incidence rate reduction for hospital-
ization-related VTE events among the ETS users was even more pronounced with
the adjusted incidence being 62% lower for ETS users relative to oral estrogen-only
HTusers.CONCLUSIONS:Results of this large population-based study showed that
patients receiving ETS had a significantly lower incidence of VTE compared to
patients receiving oral estrogen-only HT.
PCV2
THE RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH DIETARY
CALCIUM AND VITAMIN D SUPPLEMENTS IN PATIENTS WITH OSTEOPOROSIS
Chang JY1, Nichol MB2
1University of Southern California, Alhambra, CA, USA, 2University of Southern California, Los
Angeles, CA, USA
OBJECTIVES: Calcium and vitamin D supplements have been widely used and
recommended forwomen to prevent or delay the onset of osteoporosis and the risk
of bone fractures. Other benefits include the improvement of blood pressure and
lipid levels and a lowering of body weight. In theory, the beneficial effects of cal-
cium and vitamin D suggest improvements in cardiovascular health. Recent pub-
lications suggest the contrary and allude to increase serum calcium as a risk factor
for adverse cardiovascular events. This study examines whether the exposure to
these supplements are associated with cardiovascular events. METHODS: The
study was based on California Medicaid (Medi-Cal) fee-for-service administrative
claims data from January 1995 to December 2002. The study population consist of
patients50 years with recorded diagnoses of osteoporosis followed from diagno-
ses date to the end of eligibility. Patients were excluded for prior use of the supple-
ments or diagnosis of cardiovascular events or drug induced osteoporosis. Propen-
sity score matching based on age, gender, elixhauser comorbidities and eligibility
data created case (n 1594) and control groups (n4782). Chi-square analysis was
conducted for comparison of the cardiovascular events defined as ICD9 codes for
myocardial infarction and searchable terms of “cerebral infarction, hemorrhage,
ischemia” for stroke. RESULTS: No statistically significant relationship was found
between the study groups for stroke (p0.56) and myocardial infarction (p0.54).
Components of stroke included cerebral artery occlusion (p0.94), precerebral ar-
tery occlusion (p0.27), intracerebral hemorrhage (p0.23), and subarachnoid
hemorrhage (p0.05). The clinical benefits of the supplements were evident with
subarachnoid hemorrhage with 0 recorded diagnoses in the case group compared
to 12 recorded diagnosis in the control group; however statistical significance was
not established. CONCLUSIONS: The use of calcium and vitamin D supplementa-
tion yielded no relationship to the risk of adverse cardiovascular events. Moreover,
no broad cardio-protective effects can be concluded from the study.
PCV3
RISK OF HOSPITALIZATIONS FOR VENOUS THROMBOEMBOLISM IN ATYPICAL
VERSUS TYPICAL ANTIPSYCHOTIC USERS IN A NATIONAL SAMPLE OF
MEDICARE BENEFICIARIES: A CLAIMS DATA ANALYSIS
Dharmarajan SH, Yang Y, Athavale AS, Bentley JP, Null KD, Banahan BF
University of Mississippi, University, MS, USA
OBJECTIVES:To examine the difference between typical and atypical antipsychotic
drug use in the risk of hospitalization for venous thromboembolism (VTE) in an
elderly Medicare population.METHODS: This is a retrospective cohort study using
5%national sample of 2006-2007Medicare claims data. Medicare beneficiarieswith
continuous Part A, B, and D enrollment in 2006-2007 and who initiated atypical or
typical antipsychotic drug therapy in July 2006-June 2007 were included. All study
subjects were followed for a period of 180 days from the date of index prescription.
Atypical and typical users were matched on propensity score, calculated using
pre-index demographics, clinical comorbidities, andmedication use. A conditional
logistic regressionmodel stratified on the propensity score-matched pair using the
Greedymatching algorithmwas used to compare the risk of hospitalization for VTE
in new users of atypical and typical antipsychotic drugs. Sensitivity analysis in the
unmatched cohort was performed using propensity score as a continuous, linear
term in logistic regression. RESULTS: A total of 15,637 new users of atypical and
2,337 new users of typical antipsychotic drugs were identified. There were 472
(2.6%) individuals with a hospitalization for VTE during follow-up. 417 were atyp-
ical and 55 were typical antipsychotic users. A 1:1 propensity score match yielded
2,333 matched pairs (4,666 individuals). In the matched cohort, 55 typical and 64
atypical drug users were hospitalized for VTE in the follow up period. Compared to
typical antipsychotic users, users of atypical antipsychoticswere less likely to have
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